This study identified a panel of plasma biomarkers that distinguish individuals with AD from cognitively healthy control subjects with high sensitivity and specificity. Cross-validation within the AIBL cohort and further validation within the ADNI cohort provides strong evidence that the identified biomarkers are important for AD diagnosis.
No takes yet. Share an insight, caveat, or question.
James D. Doecke (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: